Citation Impact
Citing Papers
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
2017 Standout
Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
2014 Standout
Predictive Impact of Circulating Vascular Endothelial Growth Factor in Four Phase III Trials Evaluating Bevacizumab
2012
Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study
2008 Standout
Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
2012 Standout
The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia
2011 Standout
Cediranib With mFOLFOX6 Versus Bevacizumab With mFOLFOX6 As First-Line Treatment for Patients With Advanced Colorectal Cancer: A Double-Blind, Randomized Phase III Study (HORIZON III)
2012
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
2016 Standout
Hallmarks of Cancer: The Next Generation
2011 Standout
The integration of cytotoxics and biologicals in the treatment of metastatic colorectal cancer
2007
EGFR Antagonists in Cancer Treatment
2008 Standout
Mechanisms, regulation and functions of the unfolded protein response
2020 Standout
PI3K signaling in cancer: beyond AKT
2017
Pancreatic cancer
2004 Standout
A view on drug resistance in cancer
2019 StandoutNature
Ibrutinib (PCI-32765), the First BTK (Bruton’s Tyrosine Kinase) Inhibitor in Clinical Trials
2013
Breast cancer
2016 Standout
Phosphatidylinositol 3-kinase δ blockade increases genomic instability in B cells
2017 Nature
Cell cycle proteins as promising targets in cancer therapy
2017 Standout
Mechanisms of adverse effects of anti-VEGF therapy for cancer
2007
Final results of EFC6663: A multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia
2015
Rituximab
2003
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study
2015
Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future
2017 Standout
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
2008 Standout
Silencing or Fueling Metastasis with VEGF Inhibitors: Antiangiogenesis Revisited
2009
New immunosuppressants with potential implication in multiple sclerosis
2004
Global Proteome Analysis of the NCI-60 Cell Line Panel
2013
Vascular phenotypes in primary non-small cell lung carcinomas and matched brain metastases
2011
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Addition of Bevacizumab to Irinotecan- and Oxaliplatin-Based Preoperative Chemotherapy Regimens Does Not Increase Morbidity after Resection of Colorectal Liver Metastases
2007
Principles of bioactive lipid signalling: lessons from sphingolipids
2008 Standout
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
2009 Standout
Nanocarriers as an emerging platform for cancer therapy
2007 Standout
Antibody targeted drugs as cancer therapeutics
2006
Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial
2012
Clinical predictors of bevacizumab-associated gastrointestinal perforation
2010
Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study
2014
Colorectal cancer
2019 Standout
Validation of novel imaging methodologies for use as cancer clinical trial end-points
2008
Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population
2006
Antiangiogenic therapy—evolving view based on clinical trial results
2012
B-cell targeting in rheumatoid arthritis and other autoimmune diseases
2006
Chemotherapy Maintenance
2016
Graves' Ophthalmopathy
2010 Standout
Cancer as an overhealing wound: an old hypothesis revisited
2008 Standout
On the Dependency of Cellular Protein Levels on mRNA Abundance
2016 Standout
Malignant Gliomas in Adults
2008 Standout
Long-Term Results of Autologous Stem Cell Transplantation for Primary Refractory or Relapsed Hodgkin’s Lymphoma
2006
18F-FDG PET/CT bone/bone marrow findings in Hodgkin’s lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging
2010
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
2012 Standout
Diffuse large B-cell lymphoma—treatment approaches in the molecular era
2013
Chemistry in living systems
2005 StandoutNobel
Angiogenesis inhibitors in the management of breast cancer
2009
Microtubules as a target for anticancer drugs
2004 Standout
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
2015
Paul Ehrlich's magic bullet concept: 100 years of progress
2008 Standout
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray
2003 Standout
AKT/PKB Signaling: Navigating the Network
2017 Standout
Mitochondria as multifaceted regulators of cell death
2019 Standout
Reduced intensity allogeneic hematopoietic cell transplantation can induce durable remission in heavily pretreated relapsed Hodgkin lymphoma
2011
The PI3K Pathway in Human Disease
2017 Standout
Early post-transplantation positron emission tomography in patients with Hodgkin lymphoma is an independent prognostic factor with an impact on overall survival
2011
VEGF in Signaling and Disease: Beyond Discovery and Development
2019 Standout
Modes of resistance to anti-angiogenic therapy
2008 Standout
The Clavien-Dindo Classification of Surgical Complications
2009 Standout
Angiogenesis as a therapeutic target
2005 StandoutNature
Tumor Angiogenesis
2008 Standout
Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804
2007
Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy
2012 StandoutNobel
Targeting the tumour vasculature: insights from physiological angiogenesis
2010
Visceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab-based treatment in metastatic colorectal cancer
2009
Pancreatic cancer
2011 Standout
Molecular pathogenesis of mantle cell lymphoma
2012
Safety and efficacy of rituximab in patients with hepatitis C virus–related mixed cryoglobulinemia and severe liver disease
2010
Pathophysiology of Human Visceral Obesity: An Update
2013 Standout
Systematic Review: Efficacy and Safety of Rituximab for Adults with Idiopathic Thrombocytopenic Purpura
2007
Vascular remodeling and clinical resistance to antiangiogenic cancer therapy
2004
Revised Response Criteria for Malignant Lymphoma
2007 Standout
Concurrent Administration of High-Dose Rituximab Before and After Autologous Stem-Cell Transplantation for Relapsed Aggressive B-Cell Non-Hodgkin’s Lymphomas
2005
Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies
2017 StandoutNobel
Broadly neutralizing antibodies abrogate established hepatitis C virus infection
2014 StandoutNobel
Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group
2008 Standout
Unintended Consequences of Expensive Cancer Therapeutics—The Pursuit of Marginal Indications and a Me-Too Mentality That Stifles Innovation and Creativity
2014
Markers of Response for the Antiangiogenic Agent Bevacizumab
2013
Monoclonal Antibody Therapy for Cancer
2003
Inhibition of ER stress–associated IRE-1/XBP-1 pathway reduces leukemic cell survival
2014
Diffuse large cell lymphoma
2011
Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance
2009
Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
2014 Standout
The nuances of therapy
2009 Nature
T cell exclusion, immune privilege, and the tumor microenvironment
2015 StandoutScience
BFR (bendamustine, fludarabine, and rituximab) allogeneic conditioning for chronic lymphocytic leukemia/lymphoma: reduced myelosuppression and GVHD
2014
pH-Operated Nanopistons on the Surfaces of Mesoporous Silica Nanoparticles
2010 StandoutNobel
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
2014 Standout
Combined Analysis of Efficacy: The Addition of Bevacizumab to Fluorouracil/Leucovorin Improves Survival for Patients With Metastatic Colorectal Cancer
2005
Pathways Mediating Resistance to Vascular Endothelial Growth Factor–Targeted Therapy
2008
Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer
2009
Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer
2017
“Inverse Drug Discovery” Strategy To Identify Proteins That Are Targeted by Latent Electrophiles As Exemplified by Aryl Fluorosulfates
2017 StandoutNobel
Works of Eric Hedrick being referenced
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
2012
Rituximab: Ongoing and future clinical development
2002
Response-Independent Survival Benefit in Metastatic Colorectal Cancer: A Comparative Analysis of N9741 and AVF2107
2008
Ifosfamide, Carboplatin, and Etoposide: A Highly Effective Cytoreduction and Peripheral-Blood Progenitor-Cell Mobilization Regimen for Transplant-Eligible Patients With Non-Hodgkin's Lymphoma
1999
High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis
2000
A phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases.
2012
The Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 Induces Durable Responses in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Follow-up of a Phase Ib/II Study
2011
Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): Final analysis of the TREE-Study
2006
A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model
2001
Combination of the Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 with bendamustine (B)/rituximab (R) (BR) in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Interim results of a phase Ib/II study.
2012
Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE)
2008
Safety of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: Updated results from a large observational registry in the US (BRiTE)
2006
NCCTG phase II trial of bevacizumab, gemcitabine, oxaliplatin in patients with metastatic pancreatic adenocarcinoma
2006
The BTK Inhibitor, Bgb-3111, Is Safe, Tolerable, and Highly Active in Patients with Relapsed/ Refractory B-Cell Malignancies: Initial Report of a Phase 1 First-in-Human Trial
2015
Safety and Efficacy of Oxaliplatin and Fluoropyrimidine Regimens With or Without Bevacizumab As First-Line Treatment of Metastatic Colorectal Cancer: Results of the TREE Study
2008
The Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 (P) in treatment-naive (TN) chronic lymphocytic leukemia (CLL) patients (pts): Interim results of a phase Ib/II study.
2012
Post-progression therapy (PPT) effect on survival in AVF2107, a phase III trial of bevacizumab in first-line treatment of metastatic colorectal cancer (mCRC)
2004
The Bruton's Tyrosine Kinase Inhibitor PCI-32765 Is Highly Active As Single-Agent Therapy in Previously-Treated Mantle Cell Lymphoma (MCL): Preliminary Results of a Phase II Trial
2011